Rare diseases
Investigational molecules
Locations
Study Comparing bb2121 with Standard Treatments for Patients with Relapsed and Refractory Multiple Myeloma
BelgiumStudy Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant
AustriaStudy Comparing Odronextamab and Lenalidomide with Rituximab and Lenalidomide for Patients with Relapsed/Refractory Follicular and Marginal Zone Lymphoma
AustriaStudy on Brentuximab Vedotin, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
BelgiumStudy on Methotrexate, Tafasitamab, Lenalidomide, and Rituximab for Patients with Primary Central Nervous System Lymphoma Not Eligible for Stem Cell Transplant
GermanyStudy Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Patients with Untreated Multiple Myeloma Not Planning Stem Cell Transplant
CzechiaStudy of Ibrutinib and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma
CzechiaStudy on the Safety and Effectiveness of Tafasitamab and Lenalidomide for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
BulgariaStudy on Lenalidomide, Tafasitamab, and Rituximab for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older
BelgiumStudy of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma
AustriaStudy on Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Low-Risk Multiple Myeloma
GermanyLong-term Safety Study of Daratumumab with Drug Combination for Patients with Multiple Myeloma or Smoldering Multiple Myeloma
BelgiumTell us about your condition – we search every trial in Europe and connect you with the right site.
